The projected growth for cryosurgical equipment will span from 2025 to 2035 because of an increasing global cancer load accompanied by rising demand for minimally invasive approaches and expanding clinical application of cryotherapy in oncology.
The application of extreme cold through cryosurgery enables physicians to destroy problematic tissues with cancerous cells while extending its use for prostate cancer and other conditions affecting liver and cervical tissues and skin. The market outlook suggests that cryosurgical systems will experience an expansion from USD 1,232.1 million in 2025 to USD 2,401.1 million by 2035 while growing 6.9% annually.
New innovations in cryoprobe technology along with better imaging therapy guidance and fast recovery periods make cryosurgical systems more attractive to medical professionals. Oncology stands as the top application sector because both cancer cases continue to grow and this technique shows effectiveness with tissue-preserving benefits in handling small-scale tumors.
Cryosurgical equipment mainly operates within hospital settings through interventional radiology and oncology departments to execute outpatient treatments and directed cancer treatment approaches. Cryoablation adoption increases worldwide since healthcare organizations begin to acknowledge its clinical advantages.
Key Market Metrics
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 1,232.1 million |
| Industry Value (2035F) | USD 2,401.1 million |
| CAGR (2025 to 2035) | 6.9% |
Treatment adoption and healthcare investment trends in the market depend on the application areas and end user demographics specifically defined in the cryosurgical equipment sector. Cryosurgery continues to dominate the market through its tissue-saving surgical approach that patients need due to their unsuitability for invasive surgical options.
Medical facilities act as main end users to perform cryosurgical operations for treating urological, dermatological and gynaecological cancers. The integration of MRI and ultrasound imaging technologies enhances procedural accuracy in medical systems making them essential ingredients in contemporary hospital-based cancer care programs.
Explore FMI!
Book a free demo
North America holds venturous cryonation devices market owing to the larger prevalence of cancer incidence rate and high absorption of minimally invasive technologies in the region. Cryosurgery for prostate and liver cancer treatment is used in the USA and Canada in many established oncology centers.
More hospitals are outfitted with hybrid imaging, cryotherapy suites. Continued supportive reimbursement policies for surgical and non-surgical procedures, availability of clinical research funding, and hospital/facility-involved physician training programs are aiding regional market growth in terms of technology adoption.
Steady growth is being witnessed in Europe on account of growing healthcare expenditure and rising preference for organ conserving cancer therapies in the region. Nationwide oncology treatment frameworks add cryosurgery to the arsenal and countries such as Germany, France and the UK are including it.
Government-sponsored screening programs and updates in hospital infrastructure are driving demand for non-invasive cancer treatment solutions. The partnerships between academia and device manufacturers are improving technology penetration and fostering clinical application trials across the continent.
The Asia-Pacific region is becoming a rapidly expanding region of cryosurgical equipment, bolstered by rising cancer prevalence, healthcare modernization and medical tourism. The use of cryotherapy in public and private hospitals is increasing in China, Japan and India.
New portable high-quality Cryoablation units are becoming available and probes are becoming cheaper. In each region, awareness campaigns and changing clinical guidance promote the uptake of cryosurgical procedures in oncology, especially in metropolitan centers of high population density.
Limited Awareness and Cost Barriers in Emerging Markets
Clinical awareness is limited, devices are costly, and their availability is uneven in developing countries, all threatening the cryosurgical equipment industry. While cryotherapy is successful at treating tumors and tumors, skin lesions and prostate conditions, many healthcare providers are commonly not trained on administering cryotherapy and familiar with its benefits to traditional goal methods.
Furthermore, cryo units need controlled gas to be stored and handled, which can be logistically challenging with clinics that have limited infrastructure. Uncertainty about reimbursement and a failure to be included in public health systems also dampens adoption. Such barriers limit market penetration despite high growth for non-invasive and organ-saving treatment modalities.
Minimally Invasive Preferences and Expansion in Oncology
Although various restrictions for accessing the cryosurgical equipment are impacting the cryosurgical equipment market, the demand continues to grow for minimally invasive procedures in several fields including dermatology, oncology and gynaecology.
Cryoablation delivers localized treatment, causing less scarring, faster recovery times and shorter hospitalizations appealing to patients who were looking for alternatives to surgery. New technology in cryoprobe, temperature monitoring, and image-guided delivery systems are making cryoablation safer and more precise.
Cryosurgery is becoming well established as a potential adjunct to radiotherapy and chemotherapy and has been undertaken in clinical practice for breast, liver, prostate, and cervical cancers. The international trend towards outpatient and economical health services is only strengthening cryo-surgical devices as indispensable adjuncts to sophisticated treatment regimens.
The cryosurgical equipment market continued its steady growth between 2020 and 2024 as both dermatological procedures and early-stage oncology use cases drove demand. The device manufacturers concentrated on optimizing cryogen delivery devices, portability, and patient safety.
Market expansion from 2025 to 2035 will center on penetration into wider oncology, AI-assisted ablation mapping, and infusion of outpatient surgical suites. Emerging clinical applications will be driven by increasing cancer incidence, patient desire for targeted therapies, and financial commitment towards cold-based immunomodulation studies. Cryosurgery is a surrogate of minimum invasive tumor management, particularly with the advent of personalized medicine and image-guided intervention.
Market Shifts: Comparative Analysis (2020 to 2024 vs. 2025 to 2035)
| Market Factor | 2020 to 2024 |
|---|---|
| Regulatory Landscape | Device-specific safety and efficacy approvals. |
| Technological Advancements | Basic gas-based cryo units with manual controls. |
| Sustainability Trends | Limited focus on cryogen usage and energy consumption. |
| Market Competition | Led by surgical tool manufacturers and dermatology suppliers. |
| Industry Adoption | Common in skin lesion removal and prostate therapy. |
| Consumer Preferences | Interest in low-pain, scar-free, and quick recovery procedures. |
| Market Growth Drivers | Boosted by skin cancer detection and localized cancer treatments. |
| Market Factor | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Expansion into multi-indication approvals, clinical integration, and post-market surveillance. |
| Technological Advancements | Rise of image-guided, AI-assisted cryo systems with digital temperature profiling. |
| Sustainability Trends | Emphasis on gas recycling, low-energy devices, and eco-friendly storage systems. |
| Market Competition | Entry of oncology-focused medtech firms and hybrid ablation system developers. |
| Industry Adoption | Expands to oncology, gynaecology, interventional radiology, and ambulatory surgery centers. |
| Consumer Preferences | Shift toward precision, image-assisted, and outpatient cryotherapy options. |
| Market Growth Drivers | Accelerated by personalized oncology, cold therapy innovation, and outpatient care expansion. |
With the rising incidence of cancer, increasing preference for outpatient care, and technological advancement in minimally invasive surgical tools, the United States accounts for the largest market for cryosurgical equipment. Cryoablation is commonly used in prostate, breast and skin cancer, with high adoption in hospitals and ambulatory surgical centers.
Portable cryotherapy systems and closed-loop liquid-nitrogen devices for precision procedural enhancement are coming to market by USA-based companies. Increasing demand is also driven through the integration of cryosurgical units with imaging platforms such as ultrasound and CT.
| Country | CAGR (2025 to 2035) |
|---|---|
| USA | 6.7% |
The cryosurgical equipment market is also witnessing steady growth in the United Kingdom, owing to the non-invasive cancer and dermatological treatment promoted by the NHS. Cryotherapy is being used more frequently for early-stage prostate cancer, precancerous skin lesions and chronic pain management.
Next-generation Cryo-devices with real time monitoring sensor and gas efficient systems being adopted in UK clinics and hospitals. Additionally, the emphasis on shortening hospital stays and enhancing cosmetic outcomes is propelling procedural adoption.
| Country | CAGR (2025 to 2035) |
|---|---|
| UK | 6.5% |
Germany, France, and Italy are strong markets for cryosurgical equipment based on public health systems in those countries investing in minimally invasive cancer therapies. Dermatology and gynaecology segments are growing as well and are aided by market growth due to insurance coverage and patient awareness.
European manufacturers are working on innovations such as cryoprobe, multi-channel gas delivery systems, and devices that combine freezing with thermal mapping. The market outlook is also further strengthened by regulatory support for outpatient-base tumor ablation.
| Region | CAGR (2025 to 2035) |
|---|---|
| European Union | 6.9% |
The cryosurgical equipment market in Japan is also showing steady growth, driven by a rapidly aging population and a strong focus on cancer detection and treatment at early stages. Cryotherapy is a well-established treatment for tumors and benign lesions in urology and dermatology clinics with limited recovery time.
Japanese companies are developing miniaturized cryo-instruments and closed-system platforms that fit compact clinical environments. Demand is rising also in pain therapy and ophthalmology, widening the market base.
| Country | CAGR (2025 to 2035) |
|---|---|
| Japan | 6.6% |
Progressive Private Healthcare Infrastructure, Increasing Cancer Screening and Interest Men in the Cosmetic Dermatology Supplement Driving Cryosurgical Equipment Holdings for South Korea Innovative cryoablation systems are gaining traction among hospitals and specialized clinics for precise tumor removal, skin tag excision, and painless wart treatments.
South Korean manufacturers have launched easy to handle digitally controlled cryosurgical units with inexpensive gas delivery, enabling wide accessibility across the general and specialty practices.
| Country | CAGR (2025 to 2035) |
|---|---|
| South Korea | 7.4% |
The global cryosurgical equipment market has steadily evolved over the past decade, with the healthcare provider’s preference shifting towards minimizing invasiveness in procedures, designing cost effective cancer care and innovations in outpatient surgical techniques. Cryosurgery which involves using extreme cold to destroy abnormal or diseased tissue offers a highly targeted alternative to traditional surgery and radiation therapy.
By application area, oncology dominates the market on account of the growing application of cryosurgical systems for the treatment of prostate, liver, breast, and cervical cancers. In terms of delivery, the largest segment in the end-user category is hospitals, where cryosurgical systems are incorporated into surgical oncology departments, operating rooms, and specialized treatment centers. These two categories also reflect a market formed by precision medicine, clinical effectiveness, and changing cancer care protocols.
With the rising cancer incidence across the globe and expansion of healthcare technologies that facilitates faster recovery from treatment and better patient outcomes, cryosurgical equipment is increasingly becoming a first-line therapeutic option.
| Application Area | Market Share (2025) |
|---|---|
| Oncology | 59.1% |
The oncology application segment held the largest share of the cryosurgical equipment market, owing to the relative increase in applications for cryoablation, which is used to treat many tumors with least damage to the tissue with minor complications. For patients with comorbidities, or for tumors located in difficult locations, cryosurgery can provide an effective alternative to traditional surgery and/or radiotherapy.
Cryosurgical equipment for prostate, renal, liver, and breast cancer treatments is used by the hospitals, wherein freezing is guided by accuracy and works by freezing the malignant cells but only that without the healthy surrounding tissues. This approach enables both curative treatments and palliative measures, particularly in those patients who are not candidates for surgical intervention.
Ongoing innovations regarding advancements in cryogen delivery systems, real-time imaging, and thermal monitoring technology specifically will drive demand in the oncology segment. Clinicians combine cryosurgical tools with MRI and ultrasound guidance to improve targeting accuracy and visualize freeze zones. with the increasing contributions of immunotherapy and combination therapies, cryosurgery serves as a crucial adjunct to these protocols through its ability to lower tumor burden and amplify the response of the immune system.
Given the increasing global prevalence of cancer screening programs and the high demand for minimally invasive therapies, oncology will continue to be the largest application of cryosurgical equipment and the fastest growing in both developed and emerging healthcare markets.
| End User Type | Market Share (2025) |
|---|---|
| Hospitals | 62.7% |
Hospitals are the end-user segment that holds the largest share in the cryosurgical equipment market as these end users provide extensive facilities, multidisciplinary teams, and image guidance for the safe and effective execution of cryosurgical procedures. It serves as a way for these institutions to have additional modern cryoablation systems in their oncology, dermatology and pain management departments.
Cryosurgery is incorporated by hospitals for cancers and skin lesions and nerve-targeting pain therapies, in which it’s precision and speed can be crucial advantages over other modalities. Cryo devices are used by surgeons and interventional radiologists in both inpatient and outpatient settings, depending on the patient’s clinical status and complexity of the procedure.
Also, improved reimbursement policies, clinical standards, and physician training programs help hospitals use cryosurgery. North America and Europe are leading the race when it comes to installing high-performance cryotherapy systems in operating rooms and interventional suites in hospitals, whereas, hospitals in Asia-Pacific have been adopting cryosurgery as the demand for cancer care continues to rise in the region.
The hospital setting offers centralized access to imaging, anaesthesiology, and critical care support, providing the infrastructure to implement high-risk or multi-lesion cryosurgical procedures. With the continued increase in procedural volumes, greater clinical acceptance of cryosurgery and tight fiscal constraints, hospitals will lead demand and innovation with this sector.
The worldwide cryosurgical instrument market is a specialty sector of surgical and oncology technology pertaining to the use of verylow temperatures to eradicate atypical or diseased tissue in minimally intrusive surgery. Such devices are commonly used in dermatology, oncology, gynaecology, urology, and ear, nose, and throat surgeries to treat various diseases, including prostate cancer, cervical dysplasia, skin lesions, and liver tumors. Clinical interest in cryosurgical systems has grown alongside increasing demand for tissue-sparing interventions, outpatient procedures, and cost-effective ablative technologies.
There are everything from portable handheld cryoguns to more complex probe-based systems that operate on the principles of boiling liquid nitrogen, nitrous oxide, or argon gas. In this way, key players compete on probe design, thermal control accuracy, gas delivery efficiency, and procedural flexibility across clinical environments.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Medtronic plc | 20-24% |
| CooperSurgical, Inc. | 15-19% |
| Metrum Cryoflex | 12-16% |
| IceCure Medical Ltd. | 9-13% |
| CryoConcepts LP | 7-11% |
| Galil Medical (BTG International) | 6-10% |
| Other Companies (combined) | 18-26% |
| Company Name | Key Offerings/Activities |
|---|---|
| Medtronic plc | Introduced the Visual-ICE™ cryoablation system for soft tissue tumors, integrated with imaging guidance and dual-freezing modes in 2025. |
| CooperSurgical, Inc. | Expanded Wallach Cryosurgical line with ergonomic handheld cryoguns and reusable probes for gynecological applications in 2024. |
| Metrum Cryoflex | Launched Cryo-S series with open-system cryogenerators for dermatology, ENT, and oncology markets, supporting global gas compatibility in 2025. |
| IceCure Medical Ltd. | Rolled out the ProSense™ cryoablation system for breast and thyroid tumors with single-probe cryogenic precision in 2024. |
| CryoConcepts LP | Developed the CryOmega® portable handheld cryosurgery device targeting dermatology, aesthetics, and primary care in 2024. |
| Galil Medical (BTG) | Released CryoSphere™ probes with multi-zone ice field control for interventional oncology and nerve ablation in 2025. |
Key Company Insights
Medtronic plc
Medtronic leads the cryosurgical equipment market with its Visual-ICE™ platform, designed for image-guided, minimally invasive tumor ablation. Its systems are optimized for real-time monitoring, procedural customization, and seamless integration with radiology suites.
CooperSurgical, Inc.
CooperSurgical dominates the gynecological cryotherapy segment with its Wallach line, offering reusable and single-use probe options. Its systems are widely used for cervical dysplasia, delivering consistent thermal performance and clinical reliability.
Metrum Cryoflex
Metrum Cryoflex is known for modular cryosurgical workstations serving multi-specialty clinical needs. Its Cryo-S devices support a wide range of probes and gases, offering flexibility for ENT, dermatological, and oncological practices worldwide.
IceCure Medical Ltd.
IceCure is a frontrunner in liquid-nitrogen-based cryotherapy for benign and malignant tumors. Its ProSense™ system emphasizes precise tumor targeting and office-based procedures, reducing surgical overhead for breast, kidney, and thyroid interventions.
CryoConcepts LP
CryoConcepts focuses on portable, cost-effective cryosurgical tools like CryOmega®, ideal for outpatient dermatology, primary care, and aesthetic applications. Its devices require no power source or setup, appealing to non-hospital users.
Galil Medical (BTG International)
Galil specializes in advanced cryotherapy systems for interventional oncology and pain management. Its CryoSphere™ and Visual-ICE® probes are designed for large and deep lesion ablation with control over ice zone shape and freeze cycles.
Other Key Players (18-26% Combined)
Numerous regional manufacturers and specialized medical device firms contribute to the cryosurgical equipment market through adaptable designs, niche clinical solutions, and affordable consumables:
The overall market size for the cryosurgical equipment market was USD 1,232.1 million in 2025.
The cryosurgical equipment market is expected to reach USD 2,401.1 million in 2035.
The increasing prevalence of cancer, rising demand for minimally invasive treatment techniques, and growing use of cryosurgical equipment in oncology applications fuel the cryosurgical equipment market.
The top 5 countries driving the development of the cryosurgical equipment market are the USA, UK, European Union, Japan, and South Korea.
Oncology applications and hospital end users lead market growth to command a significant share over the assessment period.
Cryosurgical Equipment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
